Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.73 |
| ▸ | STS | P08842 | 2/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261473 | 0.93 | GPR119 (0.64) | GPR119STSCHEK2 | |
| SCHEMBL13324476 | 0.89 | GPR119 (0.91) | GPR119 | |
| SCHEMBL264162 | 0.86 | GPR119 (0.67) | GPR119CHEK2CA12CA1CA2 | |
| SCHEMBL3849703 | 0.86 | GPR119 (0.71) | GPR119STS | |
| SCHEMBL2555906 | 0.85 | GPR119 (1.00) | GPR119 | |
| SCHEMBL12283335 | 0.85 | GPR119 (1.00) | GPR119 | |
| SCHEMBL2555904 | 0.85 | GPR119 (1.00) | GPR119 | |
| SCHEMBL74203 | 0.83 | GPR119 (0.67) | GPR119CHEK2 | |
| SCHEMBL2735422 | 0.83 | GPR119 (0.67) | GPR119CHEK2 | |
| SCHEMBL12533230 | 0.83 | GPR119 (0.67) | GPR119STSCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| CN-107098846-B | N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-10-09 | — | — | CN | disclosed |
| US-20050245571-A1 | Amine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1437351-A1 | AMINE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275959-A1 | COMPOUNDS AND METHODS OF THEIR USE | ACSL5, ACSL3, ACSL6 | GPR119 282/4885STS 238/4885CHEK2 3324/4885 |
| US-20050245571-A1 | Amine derivative | NPY1R, SSTR1, SSTR5 | GPR119 28/4885STS 647/4885CHEK2 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.